Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

Open access
Hussain, Maha, Daignault-Newton, Stephanie, Twardowski, Przemyslaw W., Albany, Costantine, Stein, Mark N., Kunju, Lakshmi P., Siddiqui, Javed, Wu, Yi-Mi, Robinson, Dan, Lonigro, Robert J., Cao, Xuhong, Tomlins, Scott A., Mehra, Rohit, Cooney, Kathleen A., Montgomery, Bruce, Antonarakis, Emmanuel S., Shevrin, Daniel H., Corn, Paul G., Whang, Young E., Smith, David C., Caram, Megan V., Knudsen, Karen E., Stadler, Walter M., Feng, Felix Y., Chinnaiyan, Arul M. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients and Methods: Patients underwent metastatic site biopsy and were stratified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ETS fusions predicted response. Secondary objectives were: safety, measurable disease RR (mRR), progression-free survival (PFS), and molecular biomarker analysis. A total of 148 patients were randomly assigned to detect a 20% PSA RR improvement. Results: A total of 148 patients with mCRPC were randomly assigned: arm A, n = 72; arm B, n = 76. There were no differences in PSA RR (63.9% v 72.4%; P = .27), mRR (45.0% v 52.2%; P = .51), or median PFS (10.1 v 11 months; P = .99). ETS fusions did not predict response. Exploratory analysis of tumor sequencing (80 patients) revealed: 41 patients (51%) were ETS positive, 20 (25%) had DNA-damage repair defect (DRD), 41 (51%) had AR amplification or copy gain, 34 (43%) had PTEN mutation, 33 (41%) had TP53 mutation, 39 (49%) had PIK3CA pathway activation, and 12 (15%) had WNT pathway alteration. Patients with DRD had significantly higher PSA RR (90% v 56.7%; P = .007) and mRR (87.5% v 38.6%; P = .001), PSA decline ≥ 90% (75% v 25%; P = .001), and longer median PFS (14.5 v 8.1 months; P = .025) versus those with wild-type tumors. Median PFS was longer in patients with normal PTEN (13.5 v 6.7 months; P = .02), TP53 (13.5 v 7.7 months; P = .01), and PIK3CA (13.8 v 8.3 months; P = .03) versus those with mutation or activation. In multivariable analysis adjusting for clinical covariates, DRD association with PFS remained significant. Conclusion: Veliparib and ETS status did not affect response. Exploratory analysis identified a novel DRD association with mCRPC outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.75.7310

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 206

Metadata

Authors
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., Cao, X., Tomlins, S. A., Mehra, R., Cooney, K. A., Montgomery, B., Antonarakis, E. S., Shevrin, D. H., Corn, P. G., Whang, Y. E., Smith, D. C., Caram, M. V., Knudsen, K. E., Stadler, W. M., Feng, F. Y., & Chinnaiyan, A. M.
Venue
Journal of Clinical Oncology
Published
2018-04-01
Volume
36
Issue
10
Pages
991-999
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2779062531
Cited by
206
References
11
FWCI
17.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. https://app.cochat.ai/papers/10.1200/jco.2017.75.7310
The paper
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., Cao, X., Tomlins, S. A., Mehra, R., Cooney, K. A., Montgomery, B., Antonarakis, E. S., Shevrin, D. H., Corn, P. G., Whang, Y. E., . . . Chinnaiyan, A. M. (2018). Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.75.7310

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.